Dopa-responsive dystonia and Tourette syndrome in a large Danish family.

BACKGROUND Guanosine triphosphate cyclohydrolase I (GTPCH) catalyzes the first step in the synthesis of tetrahydrobiopterin (BH4). Autosomal dominantly inherited defects in the GTPCH gene (GCH1) cause a form of dystonia that is responsive to treatment with levodopa (dopa-responsive dystonia [DRD]). OBJECTIVE To investigate molecular and clinical aspects of DRD in a large Danish family. METHODS For analysis of the GCH1 gene, a mutation-scanning method based on denaturing gradient gel electrophoresis (DGGE) was used. A novel mutation, X251R, was identified in the GCH1 gene of 2 distantly related Danish patients with DRD, one of whom also had Tourette syndrome (TS). Thirty-five additional family members were investigated for this mutation, and 16 of them underwent clinical neurological examination. RESULTS A total of 18 patients were heterozygous for the X251R allele, 16 of whom had neurological complaints spanning from very mild parkinsonism to severe invalidism due to dystonia. Of 13 symptomatic heterozygotes who had been neurologically examined, 10 had signs of dystonia or parkinsonism. Sixteen of the heterozygotes were treated with levodopa, and 13 reported a treatment benefit. Three of the symptomatic heterozygotes had signs of TS. CONCLUSIONS This study confirms the large variability in DRD symptoms and emphasizes the usefulness of molecular analysis for diagnosis and treatment of DRD. The presence of TS is suggested to be coincidental, though the development of TS-like symptoms due to mutations in GCH1 cannot be excluded.

[1]  H. Ichinose,et al.  Catecholamines and Serotonin Are Differently Regulated by Tetrahydrobiopterin , 2001, The Journal of Biological Chemistry.

[2]  C. Lam,et al.  Atypical presentation of dopa-responsive dystonia , 2001, Neurology.

[3]  David E. Comings,et al.  Clinical and Molecular Genetics of ADHD and Tourette Syndrome , 2001 .

[4]  H. V. Van Tol,et al.  Polymorphisms in dopamine receptors: what do they tell us? , 2000, European journal of pharmacology.

[5]  J. Mink,et al.  Response to levodopa challenge in Tourette syndrome , 2000, Movement disorders : official journal of the Movement Disorder Society.

[6]  M. Segawa.  Hereditary progressive dystonia with marked diurnal fluctuation , 2000, Brain and Development.

[7]  Y. Agid,et al.  Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin mutations? , 2000, Brain : a journal of neurology.

[8]  D. Gilbert,et al.  Tourette’s syndrome improvement with pergolide in a randomized, double-blind, crossover trial , 2000, Neurology.

[9]  K. Hornik,et al.  Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients , 1999, European Neuropsychopharmacology.

[10]  L. Wilkins.  Bilineal transmission in Tourette syndrome , 1999 .

[11]  S J Kish,et al.  Striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia , 1999, Neurology.

[12]  S Fahn,et al.  Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Ueno,et al.  A novel missense mutant inactivates GTP cyclohydrolase I in dopa-responsive dystonia , 1999, Neuroscience Letters.

[14]  M. Shimoji,et al.  GTP Cyclohydrolase I Gene Expression in the Brains of Male and Female hph‐1 Mice , 1999, Journal of neurochemistry.

[15]  R. Surtees,et al.  GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness , 1999, Journal of neurology, neurosurgery, and psychiatry.

[16]  S. Kish,et al.  Dystonia with motor delay in compound heterozygotes for GTP‐cyclohydrolase I gene mutations , 1998, Annals of neurology.

[17]  A. Kishore,et al.  Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography , 1998, Neurology.

[18]  P. S. St George-Hyslop,et al.  Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia , 1998, Neurology.

[19]  H. Ito,et al.  Mutant GTP cyclohydrolase I mRNA levels contribute to dopa‐responsive dystonia onset , 1996, Annals of neurology.

[20]  R. Coppola,et al.  Tourette Syndrome: Prediction of Phenotypic Variation in Monozygotic Twins by Caudate Nucleus D2 Receptor Binding , 1996, Science.

[21]  L. Tsui,et al.  Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor , 1996, Nature Genetics.

[22]  C. McDougle,et al.  [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. , 1995, The American journal of psychiatry.

[23]  H. Ito,et al.  Exon skipping caused by a base substitution at a splice site in the GTP cyclohydrolase I gene in a Japanese family with hereditary progressive dystonia dopa responsive dystonia. , 1995, Biochemical and biophysical research communications.

[24]  G. Kapatos,et al.  Regulation of GTP cyclohydrolase I gene expression and tetrahydrobiopterin content by nerve growth factor in cultures of superior cervical ganglia , 1995, Neurochemistry International.

[25]  G. Kapatos,et al.  Regulation of tetrahydrobiopterin biosynthesis in cultured dopamine neurons by depolarization and cAMP. , 1994, The Journal of biological chemistry.

[26]  E. Werner,et al.  Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T 24 cells. GTP-cyclohydrolase I is stimulated by interferon-gamma, and 6-pyruvoyl tetrahydropterin synthase and sepiapterin reductase are constitutively present. , 1990, The Journal of biological chemistry.

[27]  N. Blau,et al.  BIOMDB : Database of Mutations Causing Tetrahydrobiopterin Deficiencies , 2005 .

[28]  M. Sofroniew,et al.  Nerve growth factor signaling, neuroprotection, and neural repair. , 2001, Annual review of neuroscience.

[29]  E. Kossoff,et al.  Tourette Syndrome , 2001, Paediatric drugs.

[30]  B. Cohen,et al.  Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs , 1999, Psychopharmacology.

[31]  W. Hwu,et al.  Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I mutation , 1999, Human Genetics.

[32]  C. Marsden,et al.  Atypical presentations of dopa-responsive dystonia. , 1998, Advances in neurology.

[33]  L. Tsui,et al.  Erratum: Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor (Nature Genetics (1996) 12 (280-287)) , 1996 .